MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-11-30, NRIX had $137,030K increase in cash & cash equivalents over the period. -$263,467K in free cash flow.

Cash Flow Overview

Change in Cash
$137,030K
Free Cash flow
-$263,467K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Proceeds from issuances of commo...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Deferred revenue
    • Others

Cash Flow
2025-11-30
Net loss
-264,457
Depreciation and amortization
8,740
Stock-based compensation
37,965
Net accretion of discount on marketable securities
10,322
Loss on disposal of property and equipment
-89
Amortization of operating lease right-of-use assets
10,116
Other
0
Prepaid expenses and other assets
6,229
Accounts payable
-630
Deferred revenue
-36,980
Operating lease liabilities
-5,067
Accrued expenses and other current liabilities
17,310
Net cash used in operating activities
-249,465
Purchases of marketable securities
455,688
Maturities of marketable securities
617,543
Purchases of property and equipment
14,002
Net cash provided by (used in) investing activities
147,853
Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs
234,762
Proceeds from exercise of stock options and pre-funded warrants
1,651
Proceeds from issuance of common stock under employee stock purchase plan
2,229
Proceeds from issuances of common stock in 'at the market' financing, net of issuance costs
0
Repurchase of unvested early exercised stock options
0
Net cash provided by financing activities
238,642
Net increase (decrease) in cash, cash equivalents and restricted cash
137,030
Cash and cash equivalents at beginning of period
110,898
Cash and cash equivalents at end of period
247,928
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuancesof common stock and...$234,762K Proceeds from issuance ofcommon stock under...$2,229K Proceeds from exercise ofstock options and...$1,651K Maturities of marketablesecurities$617,543K Net cash provided byfinancing activities$238,642K Net cash provided by(used in) investing...$147,853K Canceled cashflow$469,690K Net increase(decrease) in cash, cash...$137,030K Canceled cashflow$249,465K Stock-based compensation$37,965K Accrued expenses andother current...$17,310K Amortization of operatinglease right-of-use...$10,116K Depreciation andamortization$8,740K Loss on disposal ofproperty and equipment-$89K Purchases of marketablesecurities$455,688K Purchases of property andequipment$14,002K Net cash used inoperating activities-$249,465K Canceled cashflow$74,220K Net loss-$264,457K Deferred revenue-$36,980K Net accretion ofdiscount on marketable...$10,322K Prepaid expenses andother assets$6,229K Operating leaseliabilities-$5,067K Accounts payable-$630K

Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. (NRIX)